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Abstract: An investigation of the structure and drug release mechanism of a drug delivery 
system is proposed on the basis of semi-empirical and ab initio computations in vacuum 
stage. Cis-aconityl linkage is used to improve the interaction between an anti-cancer agent, 
doxorubicin,  and  a  glycol  chitosan  biopolymer.  It  has  been  found  that  the  
doxorubicin-conjugated glycol chitosan carrier has more stability. The stability is increased 
when  the  lengths  of  the  polyethylene  glycol  (PEG)  chains  in  the  glycol  chitosan 
biopolymer  are  increased.  Cis-aconityl  can  release  doxorubicin  under  appropriate 
environmental conditions. Relative energies of this mechanism in an acid condition, as 
determined by B3LYP/6-31G//PM3, are 122.41, 119.27, 160.18 and 222.22 kcal/mol, and 
by the B3LYP/6-31G//HF/6-31G method are 54.23, 109.28, 219.98 and 980.49 kcal/mol, 
with mono-, di-, tri-, and quanta-ethylene glycol, respectively. In a normal condition, the 
relative  energies  are  above  300  kcal/mol  for  all  reactions.  Therefore,  cis-aconityl  will 
release doxorubicin in an acid solution but not in a normal condition. The glycol chitosan 
polymer  can  be  degraded  in  an  acid  solution  as  well.  Long  PEG  chains  influence  the 
release mechanism of doxorubicin. The proposed length of the PEG chain is di-ethylene 
glycol. These simulation results agree well with various reported experimental data. 
Keywords: drug release; molecular modeling; glycol chitosan; doxorubicin 
 
OPEN ACCESS Int. J. Mol. Sci. 2011, 12                     
 
 
1673 
1. Introduction 
During the past decade there has been a growing interest in the investigation of polymeric carriers 
for their potential use in anticancer drug delivery. The development of chemotherapeutic agents for 
cancer  treatment  has  resulted  in  overcoming  some  tumors.  However,  these  new  chemotherapeutic 
agents still have serious side effects, such as non-specific toxicity to normal tissues, which limits the 
dosage and uses of the drug
 [1]. Consequently, to decrease the toxicity of anticancer agents to normal 
tissues, the improvement of a drug delivery system for anti-cancer drugs is of interest [2].  
Chitosan, a biopolymer which is obtained from chitin, is accepted as a biodegradable and nontoxic 
polymer. It has been widely used in the pharmaceutical and cosmetic industries as an antimicrobial 
compound.  It  is  a  cationic  polysaccharide  consisting  primarily  of  repeating  units  of  
β-(1,4)-2-amino-deoxy-D-glucose  (D-glucosamine)  [3].  The  applications  of  chitosan  are  limited 
because of its insolubility above pH 6. To increase the solubility of chitosan in water, one or two 
hydrogen atoms are removed from the amino groups of chitosan and some hydrophilic segments are 
introduced. Polyethylene glycol (PEG), as a hydrophilic segment of polymeric carriers
 [4], can freely 
dissolve  over  a  wide  pH  range.  For  most  anticancer  drug  carriers,  the  interactions  between  the 
anticancer drug and the core domain of the polymeric drug carrier rely on the balance of relatively 
weak interactions, such as hydrophobic, H-bonding, and electrostatic interactions [5,6]. 
Hence, polymeric carriers have a limitation because they disintegrate after dilution by body fluids, 
resulting in leakage of the anticancer drug into the blood vessels [7,8]. One strategy to develop a drug 
delivery system is conjugation of the anticancer drug with polymer chains by chemical linkage. This 
strategy can control the drug release rate and reduce the burst release [9,10]. 
Although various  experimental measurements  can provide information  necessary for improving 
controlled drug delivery systems, it would be highly beneficial if one could predict their performance 
by  using  computational  simulations.  Consequently,  we  investigated  the  drug  delivery  system  of 
doxorubicin-conjugated glycol chitosan via cis-aconityl linkage (GC-DOX) by a molecular modeling 
technique with two computed processes: semi-empirical PM3 and ab initio HF methods. Our hope is 
that these computational investigations can be used as a predictive tool for guiding and improving drug 
delivery system complexes. A better understanding of electronic structure can also help improve these 
drug delivery molecules. 
In this article, we propose geometrical parameters of doxorubicin-conjugated glycol chitosan via  
cis-aconityl linkage (GC-DOX) and doxorubicin in glycol chitosan by H-bonding (GC/DOX), in order 
to  compare  the  stability  of  these  two  carriers.  The  doxorubicin  release  mechanism  is  studied  for 
solution effects, including the effect of the length of PEG chains. 
2. Model and Methods 
The focused drug carrier model in this study is a doxorubicin-conjugated glycol chitosan polymer 
via cis-aconityl linkage (GC-DOX), as was used in Son et al. [1]. In order to confirm the improvement 
of the interaction between the drug and the polymer chain by cis-aconityl linkage, a GC/DOX carrier 
(see Figure 1) was modeled for comparison. Note: we used one molecule of doxorubicin conjugated 
with a tri-glucosamine ethylene glycol chain. The length of the PEG chain was increased from one up 
to five molecules in each drug carrier. Int. J. Mol. Sci. 2011, 12                     
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Figure 1. Chemical structures of (a) GC/DOX and (b) GC-DOX carriers. 
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In order to investigate doxorubicin release, a hydronium ion and water were used as models of acid 
and normal conditions, respectively. The geometries of these complexes of the doxorubi cin release 
mechanism are shown in Figure 2. Glycol chitosan degradation in solution was also studied, as well as 
the mechanism of doxorubicin release from the cis-aconityl linkage, as shown in Figure 3. 
Figure 2. The proposed doxorubicin release mechanism in acid and normal conditions. 
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Figure  3.  The  proposed  glycol  chitosan  degradation  mechanism  in  acid  and  
normal conditions. 
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Optimizations of model structure geometry were performed at the PM3 and HF/6-31G levels. PM3 
is a suitable method when there is sufficient experimental data, while HF/6-31G needs only molecular 
structure  information.  We  chose  the  density  functional  theory  (DFT)  with  the  B3LYP/6-31G 
functional, which was found to be appropriate for predicting electron structure, in order to calculate 
molecular energy. All calculations were implemented using the Gaussian 03W program [11] under the 
assumption of vacuum phase. 
3. Results and Discussion 
In this section, we report the optimized structures of the GC/DOX and GC-DOX carriers with 
various lengths of PEG chains, and the important structural parameters of these two carriers. Geometry 
optimizations of the reactant, transition state, and products of both the doxorubicin-releasing reaction 
from the linkage and the glycol chitosan-degradation reaction are represented by relative energies. 
3.1. Optimal Structures and Molecular Energies 
The optimal structures of the GC-DOX and GC/DOX carriers were obtained by both PM3 and  
HF/6-31G methods, as shown in Figures 4 and 5. It can be seen that doxorubicin in both GC-DOX and 
GC/DOX carriers, which is optimized by the HF/6-31G method, has the correct planar fused-ring 
structure,  while  the  PM3  method  results  in  a  bent  shape.  Therefore,  the  HF/6-31G  method  can 
optimize the fused-ring structure better than the PM3 method. The HF/6-31G method can also better 
optimize GC-DOX carriers with long PEG chains. Optimized long PEG chains from HF/6-31G are 
straight, but they are distorted by the PM3 method. 
H2O Int. J. Mol. Sci. 2011, 12                     
 
 
1676 
Figure 4. Optimal structures of the GC-DOX carrier by (a) PM3 and (b) HF/6-31G methods. 
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Figure 5. Optimal structures of the GC/DOX carrier by (a) PM3 and (b) HF/6-31G methods. 
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The molecular energies of both GC/DOX and GC-DOX carriers are presented in Table 1. As is 
clearly shown, the molecular energies of the GC-DOX structure are generally lower than those of 
GC/DOX. In other words, GC-DOX carriers are more stable because the cis-aconityl can formulate the 
bond between the drug and the polymer. The N-H bond length between doxorubicin and cis-aconityl is 
1.47 Å; this is shorter than the hydrogen bond, which has an approximate length of 1.8–2.0 Å. The  
N-H bond is a shorter bond because more electrons participate in bond formation. It is also a stronger 
bond;  thus  the GC-DOX carrier has  more stability.  The stability of both  GC/DOX and GC-DOX 
molecules is increased according to the length of the ethylene glycol chains. For the computed stable 
geometry  of  GC/DOX  with  a  mono-ethylene  glycol  molecule  by  HF/6-31G,  the  hydrogen  bond 
distance between O-H groups of doxorubicin and the glycol chitosan polymer is 1.95 Å. For GC/DOX 
with  penta-ethylene  glycol  molecules,  the  hydrogen  bond  is  1.86  Å.  The  interaction  between 
doxorubicin and the glycol chitosan chain is compressed by increasing the ethylene glycol units in 
PEG chains.  Int. J. Mol. Sci. 2011, 12                     
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Table 1. Molecular energies of GC/DOX and GC-DOX molecules with effect of ethylene 
glycol chain length. 
Length of ethylene glycol 
Molecular energy (A.U.) 
B3LYP/6-31G//PM3  B3LYP/6-31G//HF/6-31G 
GC/DOX  GC-DOX  GC/DOX  GC-DOX 
Mono-ethylene glycol  −4237.555  −4767.910  −4237.734  −4768.159 
Di-ethylene glycol  −4698.891  −5229.235  −4699.082  −5229.489 
Tri-ethylene glycol  −5160.238  −5690.576  −5160.426  −5690.846 
Quanta-ethylene glycol  −5621.580  −6151.916  −5621.771  −6152.184 
Penta-ethylene glycol  −6082.922  −6613.259  −6083.115  −6613.527 
3.2. Doxorubicin Release Mechanism 
This simulation studied the effect of a solution on bond-breaking between doxorubicin and the  
cis-aconityl linkage. A hydronium ion (H3O
+) was used as a model of an acid condition, and water 
(H2O) was used as a model of a normal condition. An estimation of the reaction can be calculated from 
the relative energy between the total molecular energy of the product and the total molecular energy of 
the reactant. The possibility of reaction is explained by the relative energy of each reaction step. If the 
relative energy of the product  is  negative, the reaction has  a possibility of occurring because the 
product is stable [11]. 
3.2.1. Acid Condition 
In an acid condition, a hydronium ion reacts with the N-H bonding between doxorubicin and the  
cis-aconityl linkage. Finally, the complex in the transition state (TS) separates into three molecules: 
doxorubicin, glycol chitosan bonding with the cis-aconityl cation, and water. Geometry optimizations 
of  doxorubicin  released  from  GC-DOX  with  a  mono-ethylene  glycol  complex  by  the  HF/6-31G 
method are shown in Figure 6 with their relative energies. The relative energy in the transition state is 
greater than the reactant because the hydronium ion needs “activated energy” at least 54.23 kcal mol
−1 
to react with the doxorubicin and cis-aconityl bonding. Relative energies for the release mechanism of 
doxorubicin with a PEG chain are shown in Table 2. Int. J. Mol. Sci. 2011, 12                     
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Figure  6.  Relative  energies  and  geometries  of  the  stationary  states  of  the  doxorubicin 
release mechanism of GC-DOX with mono-ethylene glycol in an acid condition, by the 
HF/6-31G method. 
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Table 2. Relative energies of the doxorubicin release mechanism in an acid condition.
The  activated  energies  of  doxorubicin  released  from  each  reaction  in  an  acid  condition  by  
B3LYP/6-31G//PM3  are  122.41,  119.27,  160.18  and  222.22  kcal/mol  with  mono-,  di-,  tri-  and 
quanta(ethylene glycol), respectively. On the other hand, B3LYP/6-31G//HF/6-31G gives energies of 
54.23,  109.28,  219.98  and  980.49  kcal/mol  for  mono-,  di-,  tri-,  and  quanta(ethylene  glycol), 
respectively.  The  length  of  the  PEG  chain  influences  the  bond-breaking  of  doxorubicin  and  the 
linkage: the longer the PEG chains, the more difficult the bond-breaking. Since the PEG chains have a 
steric  hindrance  effect  which  disturbs  the  hydronium  ion’s  interaction  with  the  nitrogen  atom  in 
doxorubicin, the reaction needs high activated energy. 
Length of PEG  Reaction steps 
Relative energy (kcal/mol) 
B3LYP/6-31G//PM3  B3LYP/6-31G//HF/6-31G 
1-PEG 
Reactant  0.00    0.00   
TS  122.41    54.23   
Product  −95.64    −77.84   
2-PEG 
Reactant  0.00    0.00   
TS  119.27    109.28   
Product  −113.31    −77.61   
3-PEG 
Reactant  0.00    0.00   
TS  160.18    219.98   
Product  −96.31    −69.53   
4-PEG 
Reactant  0.00    0.00   
TS  222.22    980.49   
Product  −99.65    −73.39   Int. J. Mol. Sci. 2011, 12                       
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3.2.2. Normal Condition 
In a normal condition, the water molecule is attracted to the N-H bonding between doxorubicin and 
the cis-aconityl linkage (see Figure 2). The activated energies of doxorubicin released from GC-DOX 
in a normal condition by the B3LYP/6-31G//PM3 method are 379.06, 342.03 and 433.77 kcal/mol 
with  mono-,  di-  and  tri(ethylene  glycol),  respectively.  The  respective  energies  from  the  
B3LYP/6-31G//HF/6-31G  method  are  387.94,  325.67  and  444.78  kcal/mol,  as  shown  in  Table  3. 
According to both semi-empirical PM3 and ab initio HF/6-31G methods, the activated energies of the 
release  mechanism  of  the  three  reactions  in  a  normal  condition  are  much  higher  than  in  an  acid 
condition. This high amount of energy will obstruct the possibility of a reaction. Therefore, we stopped 
the simulation in normal condition at 3-PEG. Consequently, the cis-aconityl linkage cannot release the 
doxorubicin molecule from the GC-DOX carrier in a normal environment. 
Table 3. Relative energies of the doxorubicin release mechanism in a normal condition. 
Length of PEG  Reaction steps 
Relative energy (kcal/mol) 
B3LYP/6-31G//PM3  B3LYP/6-31G//HF/6-31G 
1-PEG 
Reactant  0.00    0.00   
TS  379.06    387.94   
Product  −93.70    −43.97   
2-PEG 
Reactant  0.00    0.00   
TS  342.03    325.67   
Product  −95.06    −58.54   
3-PEG 
Reactant  0.00    0.00   
TS  433.77    444.78   
Product  −107.88    −50.78   
These results in acid and normal conditions correspond with the experimental data from Son et al. [1]. 
They studied doxorubicin released from DOX/GC-DOX in different pH media. Their report showed 
that  the  cis-aconityl  linkage  is  pH-sensitive  with  hydrolysis
  [1,12]
  in  an  acidic  environment. 
Doxorubicin  was  released  continuously  from  nanoaggregations  at  pH  4,  while  the  release  of 
doxorubicin was almost negligible at pH 7. The bloodstream is a normal environment (pH 7.4), which 
has  no  effect  on  doxorubicin  and  linkage  bonding.  Since  cis-aconityl  is  pH-sensitive  and  helps 
stabilize the formation, it can control drug leakage in blood vessels before the target cells are reached. 
When  these  drug  carriers  contact  the  target  cell,  they  can  release  the  drug  via  lysozymes  from 
lysosome organelles which function well in an acid solution of pH 4.5. 
3.3. Glycol Chitosan Degradation 
During  doxorubicin  release,  glycol  chitosan  polymers  will  also  be  degraded.  This  part  of  the 
simulation  used  di-glucosamine(ethylene  glycol)  to  represent  the  glycol  chitosan  polymer.  The 
reaction  of  glycol  chitosan  degradation  was  studied  under  both  acid  and  normal  conditions; 
doxorubicin  release  under  these  conditions  was  studied  as  well.  The  reaction  possibility  can  be 
calculated from the relative energy between the total molecular energy of the product and the total 
energy of the reactant, in the same manner as described in the previous section.  Int. J. Mol. Sci. 2011, 12                       
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3.3.1. Acid Condition 
The results showed that the hydrogen atom in the hydronium ion interacts with the oxygen atom of  
di-glucosamine(ethylene glycol) in the transition state. There are three different molecules in the final 
step: the glucosamine(ethylene glycol) cation, glucosamine(ethylene glycol), and water. The reaction 
steps  of  glycol  chitosan  degradation  in  an  acid  condition  by  the  HF/6-31G  method  are  shown  in  
Figure 7. The effects of the lengths of ethylene glycol chains on the reaction are shown in Table 4. 
Figure  7.  Relative  energies  and  geometries  of  stationary  states  of  the  glycol  chitosan  
bond-breaking mechanism in an acid condition, by the HF/6-31G method. 
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Table  4.  Relative  energies  of  the  glycol  chitosan  bond-breaking  mechanism  in  an  
acid condition. 
Length of PEG  Reaction steps 
Relative energy (kcal/mol) 
B3LYP/6-31G//PM3  B3LYP/6-31G//HF/6-31G 
  Reactant  0.00    0.00   
1-PEG  TS  145.45    97.00   
  Product  −17.77    −13.41   
  Reactant  0.00    0.00   
2-PEG  TS  91.12    62.59   
  Product  −16.60    −18.70   
  Reactant  0.00    0.00   
3-PEG  TS  61.41    44.11   
  Product  −6.61    −14.00   
  Reactant  0.00    0.00   
4-PEG  TS  43.04    32.68   
  Product  −4.06    18.74   
  Reactant  0.00    0.00   
5-PEG  TS  33.63    35.31   
  Product  62.85    27.52   Int. J. Mol. Sci. 2011, 12                       
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The activated energies of the reaction of di-glucosamine(ethylene glycol) in an acid condition are 
145.45, 91.12, 61.41, 43.04 and 33.63 kcal/mol for mono-, di-, tri-, quanta- and penta(ethylene glycol), 
respectively, by the B3LYP/6-31G//PM3 method. The activated energies from B3LYP/6-31G//HF/6-31G 
are 97.00, 62.59, 44.11, 32.31 and 35.31 kcal/mol for mono-, di-, tri-, quanta- and penta(ethylene 
glycol),  respectively.  Polyethylene  glycol  (PEG)  affects  glycol  chitosan  bond-breaking.  When  the 
length of the ethylene glycol chain is increased, it can decrease the activated energy of the reaction. 
In the product stage, the semi-empirical PM3 method shows that reactions which consist of mono-, 
di-, tri- and quanta (ethylene glycol) have the potential to occur. However, since the relative energy of 
the product in the di-glucosamine penta(ethylene glycol) bond-breaking reaction has a positive value, 
the product is unstable, and hence will not occur. Reactions that do not have potential when simulated 
by the ab initio HF/6-31G method are di-glucosamine with quanta- and penta(ethylene glycol). 
3.3.2. Normal Condition 
For the glucosamine (ethylene glycol) bond-breaking mechanism in a normal condition, a water 
molecule was used as a model. The products are two glucosamine (ethylene glycol) molecules. The 
relative energies of their reactions with the effect of the PEG chain are presented in Table 5.  
Table  5.  Relative  energies  of  the  glycol  chitosan  bond-breaking  mechanism  in  a  
normal condition. 
B3LYP/6-31G//PM3 simulation demonstrates that the activated energies in a normal condition are 
456.92,  364.29,  412.88  and  409.54  kcal/mol  for  mono-,  di-,  tri-  and  quanta(ethylene  glycol), 
respectively; while B3LYP/6-31G//HF/6-31G gives respective energies of 474.96, 460.33, 464.98 and 
451.65 kcal/mol for mono-, di-, tri- and quanta(ethylene glycol). It can be seen that all these reactions 
consume high amounts of activated energy, and that the product energies of all reactions are positive 
values, which point to their unstable state. Therefore, glycol chitosan cannot be degraded in a normal 
solution.  The  simulation  results  in  this  section  correspond  well  with  experimental  results  from  
Saito et al.
 [13], who reported that chitosan could be stable in a water solution but is degraded in an 
acidic solution, because H
+ in acid can more easily act on the GC-DOX bond than H2O can. 
Length of PEG  Reaction steps 
Relative energy (kcal/mol) 
B3LYP/6-31G//PM3  B3LYP/6-31G//HF/6-31G 
  Reactant  0.00    0.00   
1-PEG  TS  456.92    474.96   
  Product  22.75    3.87   
  Reactant  0.00    0.00   
2-PEG  TS  364.29    460.33   
  Product  17.71    3.50   
  Reactant  0.00    0.00   
3-PEG  TS  412.88    464.98   
  Product  14.70    2.69   
  Reactant  0.00    0.00   
4-PEG  TS  409.54    451.65   
  Product  10.71    0.81   Int. J. Mol. Sci. 2011, 12                       
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The pathway of GC-DOX carriers starts from injection into a blood vessel. The loaded doxorubicin 
in  GC-DOX  carriers  cannot  be  released  under  the  pH  7.4  condition  of  blood  vessels,  which 
corresponds  with  the  simulation.  After  the  GC-DOX  carriers  are  distributed  to  cancer  cells,  the 
endocytosis mechanism will transport the GC-DOX carriers into vesicles. These vesicles permeate the 
endosome  and  reach  the  lysosome  compartments.  There,  doxorubicin  molecules  are  released  by 
lysosomal enzymes called lysozymes. The released doxorubicin molecules move to the nucleus in order 
to inhibit the growth of cancer cells. Following the release of doxorubicin, some of the used drug carriers 
are degraded by lysozymes and are then reabsorbed by vesicles in a process called exocytosis, to later be 
completely digested in other compartments. Finally they are excreted from the body in urine via the 
kidneys or in bile [14].  
4. Conclusions 
In this article, we analyzed the stability of the drug carrier doxorubicin-conjugated glycol chitosan 
polymer via cis-aconityl linkage (GC-DOX), and the doxorubicin release mechanism by a molecular 
modeling method. The GC-DOX carrier improved the interaction by controlling the leakage of loaded 
doxorubicin from carrier molecules. The cis-aconityl linkage can release doxorubicin even under the 
acidic environment effect of lysozyme. In the human body, doxorubicin is released by lysozymes, 
which work well under acid conditions. After the doxorubicin is released, the glycol chitosan carrier 
will then be degraded by this enzyme. From the simulation, the PEG chain plays a major role in drug 
carrier formation and the drug release reaction. The optimal length of the PEG chain for this GC-DOX 
system is di-ethylene glycol (2-PEG), due to the fact that long PEG chains influence the doxorubicin 
release  mechanism  and  the  degradation  of  glycol  chitosan.  Even  though  there  was  satisfactory 
agreement with experimental data from the literature of the simulations by the semi-empirical PM3 
and ab initio HF/6-31G methods under the assumption of vacuum phase, we would not recommend 
that this result be directly considered as it is still experimental work.  
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